BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30650563)

  • 1. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.
    Klingler M; Rangger C; Summer D; Kaeopookum P; Decristoforo C; von Guggenberg E
    Pharmaceuticals (Basel); 2019 Jan; 12(1):. PubMed ID: 30650563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
    J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
    Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
    Laverman P; Béhé M; Oyen WJ; Willems PH; Corstens FH; Behr TM; Boerman OC
    Bioconjug Chem; 2004; 15(3):561-8. PubMed ID: 15149184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
    von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
    Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
    J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
    Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
    Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
    von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
    Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.
    Wayua C; Low PS
    J Nucl Med; 2015 Jan; 56(1):113-9. PubMed ID: 25500824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricine co-ligand improved the efficacy of
    Shaghaghi Z; Abedi SM; Hosseinimehr SJ
    Biomed Pharmacother; 2018 Aug; 104():325-331. PubMed ID: 29775901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated Synthesis of
    Hörmann AA; Plhak E; Klingler M; Rangger C; Pfister J; Schwach G; Kvaternik H; von Guggenberg E
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335396
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.